AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026

Reuters

Sep 30

AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026

**AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating "Royalty Management Co," which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and "Biopharma Co," which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571508413"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571508413\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571508413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571508413","market":"fut","top_or_hot":-1,"title":"AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"<a href=\"https://laohu8.com/S/RMCO\">Royalty Management</a> Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"<a href=\"https://laohu8.com/S/RMCO\">Royalty Management</a> Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL9wn2Lc:1","article_id":"2571508413","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571508413","pubTimestamp":1759176358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. , a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"Royalty Management Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","ANAB":"Anaptysbio Inc","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股"},"translate_title":"AnaptysBio将在2026年底前拆分为两家上市公司，分离生物制药业务和特许权使用费资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ANAB":0.9},"content_text":"AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n    \n\n        **AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"Royalty Management Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}